Kestra Medical TechnologiesKMTS
Recorded

Kestra Medical Technologies Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Rick WiseAnalyst

Alrighty, let's get going. It is my very distinct pleasure to welcome Kestra Medical. To my left, Brian Webster, President, CEO, and Director, and to Brian's left, Vaseem Mahboob, Chief Financial Officer. Welcome to you both. Thank you so much for being here. We were just talking before we got started, and it just feels like Kestra continues to execute excellently well. Thank you for the consistent performance. The company, since coming public in March 2025, has continued to build on its commercial presence in wearable cardioverter defibrillators, or WCDs, as a reminder. Brian, let's just get right into it. I was reflecting on my initial launch of coverage, and the story was, you're bringing a differentiated alternative into a well-established market with one competitor. But since you've launched, the WCD market growth has essentially doubled, reaching 14% on dollar basis in the last fiscal year.

Rick WiseAnalyst

At the highest level, talk to us about those market dynamics that led to that. Is that sustainable, that faster growth? Just at a high level, what's it mean for Kestra's growth outlook from here?

Brian WebsterPresident, CEO, and Director

Yeah. Well, thank you for the question, and thanks for the invitation to be here. Always great to see you.

Brian WebsterPresident, CEO, and Director

Likewise. I think what's first and foremost, you have to remember that the whole reason that Kestra became a company and that we took a shot at this was we felt like there was a patient problem that needed to be solved.

Brian WebsterPresident, CEO, and Director

That was these patients were not willing to wear the competitive product because of the issues around wearability, comfort, gender specificity, false alarms, all the things that we know to be the issues, and we set out to go solve those, and we've solved those. So now it's a question of how do we get that product out into the hands of more of these patients? So, solving the problem, the clinical problem was job one.

Brian WebsterPresident, CEO, and Director

I think, anytime you disrupt a monopoly and you sort of wake them up, I think in med tech there's plenty of precedents where you've seen companies that come into a market like that, and then the market tends to grow faster because there's somebody else amplifying the marketing message for the category. We've had a lot of good clinical evidence that has come forward in the last couple of years. We, of course, published our post-approval study data, which was 21,000 patients worth of data, which was fantastic. Our competitor published their own data about another 19,000 patients worth of data. You have, between those two, 40,000 patients worth of clinical data on the category.

Brian WebsterPresident, CEO, and Director

In one important respect, it was all saying the same thing, which is there's a part of this patient population that is at higher risk than everybody understood, and that's the non-ischemic cardiomyopathy or the heart failure type patients who have higher risk of cardiac arrest than physicians really understood. We're out there, we're pushing that message, our competitor is pushing that message, and part of that is now being adopted by these physicians because they're saying, "Hey, I need to think about the spectrum of my patients a little bit differently." I think it's a combination of all those things that's leading to the market growth. At the end of the day, there's still 850,000 patients a year that are indicated for a WCD, and only one in seven are being prescribed one.

Brian WebsterPresident, CEO, and Director

To your question about how durable is the growth, we think it's going to be a growth story for a long time, the market growth. Kestra, obviously, we think we have opportunity for really exciting growth for an extended period of time. We think that's durable because there's so many more patients that can be eligible for a product like the WCD.

Rick WiseAnalyst

Another aspect of growth, of course, is innovation. Brian, on the September call, you outlined AI opportunities in patient support, revenue access, collections, commercial productivity. Can you help flush that out for us a little bit more? What's already happening versus what's being tested? How do these kinds of tools change the patient experience or the sales rep's day, or what's it mean to the outlook for Kestra?

Brian WebsterPresident, CEO, and Director

Well, I think we think about AI in two big broad ways. One way is to assist us with operating the business model, and the other is to assist us in improving the product offerings, right? On the business model side, we focus it in three places right now. One is outbound connection with patients. It is a rental model, remember, so we have to go get those devices and get them back so we can refurb them and get them back out to the next patient. So that whole process of how you contact a patient, how you confirm with the patient, how you deliver the return processing, all those things have been manual, but we are automating those with specific customized agents that will work on our behalf. So that is one way.

Brian WebsterPresident, CEO, and Director

Then you have the inbound customer care activities, communication with patients, solving simple issues that a bot can solve. I would call that just standard customer care kind of leverage. The second big area on the operational side is all the things in revenue cycle management. It is very transactional, right? Every day, there are many transactions, prior authorizations that have to go out to a payer. Our AI should be able to talk to the payer AI and get the prior auth done without human intervention. Things like the medical record reviews that have to happen to be able to submit a claim, we can do that, and we are doing that today with AI instead of humans. We used to have a clinical team that would do that. Now we use AI to do that very effectively, by the way.

Brian WebsterPresident, CEO, and Director

Just all of the areas in rev cycle that are real process-oriented, it is an opportunity as we scale the company up to implement AI to bend the curve so that we do not have to ultimately hire as many people to do the same job. Finally, on the operational side of the business, we use AI to help our sales teams be more productive. It is all the way from territory planning to individual account planning. All of the tools that we have, we put at their disposal so they can do a great job of targeting, figuring out where they are going to spend their time, how to prioritize their day, and ultimately, that leads to productivity.

Rick WiseAnalyst

I assume share retention and- Yeah customer loyalty, et cetera, and better outcomes, obviously, for patients.

Rick WiseAnalyst

Also on the September call, intriguingly, because I've been asking you since pre-IPO what else was in the pipeline, and you've been very discreet. You highlighted, described a late-stage project that would extend ASSURE's performance, adding a capability that does not exist on WCDs. You said you were going to share more over the next quarter. Well, here we are. Feel free.

Brian WebsterPresident, CEO, and Director

Well, the quarter's not over yet, so we're not quite ready to dive in on that particular one yet, but we're getting close, and I think before the end of the calendar year, we'll certainly be ready to do that.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day